Group 1 - The core business of the company is the research, production, sales, and service of medical devices, with a wide range of products including blood glucose systems, blood pressure monitors, and various medical supplies [2] - As of the first quarter of 2025, the company reported a revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2] - The company has received several honors, including being recognized as a potential brand in the Chinese drug retail market for 2023-2024 and as a leading brand for assistive devices in Hunan Province [2] Group 2 - The company's current price-to-earnings (PE) ratio is 22.92, significantly lower than the industry average of 49.40 and the industry median of 36.13, ranking it 50th in the industry [1][3] - The total market capitalization of the company is 6.921 billion yuan [1] - As of the first quarter of 2025, 17 institutions hold shares in the company, with a total holding of 27.4022 million shares valued at 938 million yuan [1]
可孚医疗收盘下跌1.02%，滚动市盈率22.92倍，总市值69.21亿元